Leveraging drug conjugate technology to selectively deliver medicine to regenerate bone

Meet the people Science

Latest News

11.17.20
David C. Dvorak joins Mesentech's Board of Directors

11.17.20
Barbara Yanni joins Mesentech's Board of Directors

11.10.20
CureDuchenne Ventures, and Charles H. Hood Foundation invest in Mesentech for development of Novel Duchenne Muscular Dystrophy Therapy

More